(Q36916868)

17 August 2017

1 reference

title

IPdR: a novel oral radiosensitizer (English)

1 reference

17 August 2017

Muhammad Wasif Saif

1

1 reference

17 August 2017

Greg Berk

series ordinal

2

1 reference

17 August 2017

Yung-Chi Cheng

series ordinal

3

1 reference

17 August 2017

Timothy James Kinsella

series ordinal

4

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

16

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

1415-1424

1 reference

Radiosensitizing nucleosides

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

Anti-herpes simplex virus activity of 5-substituted 2-pyrimidinone nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

Characterization of camptothecin-resistant chinese hamster lung cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyribose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastom

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

Treatment of locally advanced cancer of the head and neck with 5'-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

An interaction of cisplatin and radiation in two rat yolk sac tumour cell lines with different radiosensitivities in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

Carboplatin as a potentiator of radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1415

10.1517/13543784.16.9.1415

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference